Unknown

Dataset Information

0

Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1H)-pyrazole Derivatives as JAKs Inhibitors.

ABSTRACT: Abnormalities in the JAK/STAT signaling pathway lead to many diseases such as immunodeficiency, inflammation, and cancer. Herein, we designed and synthesized a series of 4-amino-(1H)-pyrazole derivatives as potent JAKs inhibitors for cancer treatment. Results from in vitro protein kinase inhibition experiments indicated that compounds 3a-f and 11b are potent JAKs inhibitors. For example, the IC50 values of compound 3f against JAK1, JAK2, and JAK3 were 3.4, 2.2, and 3.5 nM, respectively. In cell culture experiments, compound 3f showed potent antiproliferative activity against various cell lines (PC-3, HEL, K562, MCF-7, and MOLT4) at low micromolar levels, while compound 11b showed selective cytotoxicity at submicromolar levels against HEL (IC50: 0.35 ?M) and K562 (IC50: 0.37 ?M) cell lines. It is worth noting that both 3f and 11b showed more potent antiproliferative activities than the approved JAKs inhibitor Ruxolitinib.

SUBMITTER: Liang X 

PROVIDER: S-EPMC5066150 | biostudies-literature | 2016 Oct

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Design, Synthesis, and Antitumor Evaluation of 4-Amino-(1<i>H</i>)-pyrazole Derivatives as JAKs Inhibitors.

Liang Xuewu X   Zang Jie J   Zhu Mengyuan M   Gao Qianwen Q   Wang Binghe B   Xu Wenfang W   Zhang Yingjie Y  

ACS medicinal chemistry letters 20160823 10

Abnormalities in the JAK/STAT signaling pathway lead to many diseases such as immunodeficiency, inflammation, and cancer. Herein, we designed and synthesized a series of 4-amino-(1<i>H</i>)-pyrazole derivatives as potent JAKs inhibitors for cancer treatment. Results from <i>in vitro</i> protein kinase inhibition experiments indicated that compounds <b>3a</b>-<b>f</b> and <b>11b</b> are potent JAKs inhibitors. For example, the IC<sub>50</sub> values of compound <b>3f</b> against JAK1, JAK2, and J  ...[more]

Similar Datasets

Unknown Design, Synthesis and Anticandidal Evaluation of Indazole and Pyrazole Derivatives.
| S-EPMC7996157 | biostudies-literature
Unknown Design, synthesis and molecular modelling studies of some pyrazole derivatives as carbonic anhydrase inhibitors.
| S-EPMC6896446 | biostudies-literature
Unknown Design, synthesis and primary activity evaluation of L-arginine derivatives as amino-peptidase N/CD13 inhibitors.
| S-EPMC7125801 | biostudies-literature
Unknown Design, synthesis and antitumor activity of 5-trifluoromethylpyrimidine derivatives as EGFR inhibitors.
| S-EPMC9542405 | biostudies-literature
Unknown Design, synthesis and <i>in vitro</i> biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment.
| S-EPMC7006757 | biostudies-literature
Unknown Design, synthesis and biological evaluation of 3,5-disubstituted 2-amino thiophene derivatives as a novel class of antitumor agents.
| S-EPMC4170804 | biostudies-literature
Unknown Betulinic Acid-Nitrogen Heterocyclic Derivatives: Design, Synthesis, and Antitumor Evaluation in Vitro.
| S-EPMC7070564 | biostudies-literature
Unknown Design, synthesis, and biological evaluation of pyrazole-linked aloe emodin derivatives as potential anticancer agents.
| S-EPMC8152798 | biostudies-literature
Unknown Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
| S-EPMC6680717 | biostudies-literature
Unknown Design, synthesis, and biological evaluation of 3-vinyl-quinoxalin-2(1H)-one derivatives as novel antitumor inhibitors of FGFR1.
| S-EPMC4861610 | biostudies-literature